NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03363841,Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES),https://clinicaltrials.gov/study/NCT03363841,CARES,COMPLETED,"This is a multicenter, open-label, non-comparator, single-arm study to evaluate the efficacy, safety, tolerability and PK (pharmacokinetics) of oral SCY-078 as an emergency use treatment for patients with a documented Candida auris infection.",YES,"Candidiasis, Invasive|Candidemia",DRUG: SCY-078,"Percentage of Participants With Global Success at End of Treatment as Determined by the Data Monitoring Committee, The percentage of participants with global success at End of Treatment (EoT) as determined by the Data Monitoring Committee. Global success is defined as complete or partial resolution of signs and symptoms associated with the fungal disease and mycological eradication., At (EoT) Visit (up to 90 days after Day 1)","Percent of Participants With Treatment-emergent Adverse Events, Percent of participants with treatment-emergent Adverse Events (TEAEs), Through study completion, up to 132 days|Number of Participants Discontinued Due to Adverse Events, Number of participants with Discontinuations due to Adverse Events, Through study completion (up to 132 Days)|Percentage of Participants With Recurrence of Baseline Fungal Infection, The percentage of participants with a recurrence of the baseline fungal infection at the 6 week follow-up, 42 Days after the End of Treatment visit|Percentage of Participants Surviving 42 and 84 Days, Percentage of participants Surviving at Day 42 and Day 84 after Day 1 (first dose of study drug), Day 42 and Day 84 after first dose of study drug",,"Scynexis, Inc.",,ALL,"ADULT, OLDER_ADULT",PHASE3,30,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,SCY-078-305,2017-11-15,2023-04-14,2023-05-24,2017-12-06,2024-07-03,2024-07-03,"Scynexis, Inc., Jersey City, New Jersey, 07302, United States|St John's Medical College and Hospital, Bangalore, Karnataka, 560034, India|Amrita Institute of Medical Sciences (AIMS), Kanayannur, Kochi, 682041, India|Institute of Critical Care Medicine Max Super Specialty Hospital, Saket, New Delhi, 110017, India|King George Medical University, Lucknow, Uttar Pradesh, 226003, India|Postgraduate Institute of Medical Education and Research, Department of Anaesthesia and special care, Chandigarh, 160012, India|Aga Khan University Hospital, Karachi, Sindh, 74800, Pakistan|Johese Clinical Research, Unitas Hospital Centurion,, South Africa, 0157, Centurion, Gauteng, 0157, South Africa|Emmed Research, Jakarta Hospital, Pretoria, Gauteng, 0002, South Africa|Into Research, Life Groenkloof Hospital, Pretoria, Gauteng, 0181, South Africa|Johese Clinical Research, Midstream, Pretoria, Gauteng, 1692, South Africa|Zuid Afrikaans Hospital, Pretoria, 0002, South Africa","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/41/NCT03363841/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/41/NCT03363841/SAP_001.pdf"
